CN1778340B - Chinese medicine composition for treating coronary heart disease and angina cordis - Google Patents
Chinese medicine composition for treating coronary heart disease and angina cordis Download PDFInfo
- Publication number
- CN1778340B CN1778340B CN 200410072945 CN200410072945A CN1778340B CN 1778340 B CN1778340 B CN 1778340B CN 200410072945 CN200410072945 CN 200410072945 CN 200410072945 A CN200410072945 A CN 200410072945A CN 1778340 B CN1778340 B CN 1778340B
- Authority
- CN
- China
- Prior art keywords
- film
- ultrafiltration
- chinese medicine
- medicine composition
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims description 26
- 208000029078 coronary artery disease Diseases 0.000 title abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 26
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 26
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 13
- 238000000108 ultra-filtration Methods 0.000 claims description 117
- 239000012528 membrane Substances 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 34
- 239000009636 Huang Qi Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 18
- 229920002492 poly(sulfone) Polymers 0.000 claims description 17
- 230000000737 periodic effect Effects 0.000 claims description 12
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 10
- 229920006393 polyether sulfone Polymers 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 235000015073 liquid stocks Nutrition 0.000 claims description 9
- 239000011550 stock solution Substances 0.000 claims description 9
- 229920001747 Cellulose diacetate Polymers 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 229920002301 cellulose acetate Polymers 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002033 PVDF binder Substances 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 229910052756 noble gas Inorganic materials 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 239000004695 Polyether sulfone Substances 0.000 claims description 4
- 238000000703 high-speed centrifugation Methods 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 238000001471 micro-filtration Methods 0.000 claims description 4
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 238000005352 clarification Methods 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- KXJGSNRAQWDDJT-UHFFFAOYSA-N 1-acetyl-5-bromo-2h-indol-3-one Chemical compound BrC1=CC=C2N(C(=O)C)CC(=O)C2=C1 KXJGSNRAQWDDJT-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 238000011017 operating method Methods 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- 229940116229 borneol Drugs 0.000 abstract 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 2
- 235000005412 red sage Nutrition 0.000 abstract 2
- 238000007493 shaping process Methods 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 238000004140 cleaning Methods 0.000 description 29
- 238000005516 engineering process Methods 0.000 description 25
- 239000000126 substance Substances 0.000 description 25
- 238000011001 backwashing Methods 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 238000001914 filtration Methods 0.000 description 11
- 239000008187 granular material Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 108090000862 Ion Channels Proteins 0.000 description 7
- 102000004310 Ion Channels Human genes 0.000 description 7
- 239000005708 Sodium hypochlorite Substances 0.000 description 7
- 238000000429 assembly Methods 0.000 description 7
- 230000000712 assembly Effects 0.000 description 7
- 238000011010 flushing procedure Methods 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 7
- 239000012535 impurity Substances 0.000 description 6
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 5
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 5
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 5
- 229960003321 baicalin Drugs 0.000 description 5
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000002949 phytic acid Nutrition 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 4
- 239000004383 Steviol glycoside Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- -1 flavone glycoside Chemical class 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 229940068041 phytic acid Drugs 0.000 description 4
- 239000000467 phytic acid Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229930182488 steviol glycoside Natural products 0.000 description 4
- 235000019411 steviol glycoside Nutrition 0.000 description 4
- 150000008144 steviol glycosides Chemical class 0.000 description 4
- 235000019202 steviosides Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001061264 Astragalus Species 0.000 description 3
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 3
- 235000006533 astragalus Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000002481 ethanol extraction Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 238000009495 sugar coating Methods 0.000 description 3
- 241001269238 Data Species 0.000 description 2
- 241000218628 Ginkgo Species 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 208000007718 Stable Angina Diseases 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000008394 flocculating agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 description 1
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000005493 condensed matter Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011987 exercise tolerance test Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940093252 sorbitrate Drugs 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
A Chinese medicine for treating coronary heart disease and angina pectoris is prepared from red sage root, notoginseng, borneol and astragalus root through extracting the liquid extract from red sage root, notoginseng and astragalus root in water or alcohol, clarifying, ultrafiltering, concentrating, adding borneol and shaping.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition of using the ultrafiltration technology preparation.Particularly, the present invention relates to a kind of Chinese medicine composition of using the treatment angina pectoris of ultrafiltration technology preparation.
Background technology
FUFANG DANSHEN PIAN is that Chinese Pharmacopoeia is gone through the kind recorded of version, has the effect of blood circulation promoting and blood stasis dispelling, regulating QI to relieve pain, be used for feeling oppressed in the heart, angina pectoris, and be medicine commonly used clinically at present.Its traditional handicraft is: gets Radix Salviae Miltiorrhizae and extracts 3 times, added alcohol reflux 1.5 hours the 1st time, filter, and filtrate recycling ethanol, being concentrated into relative density is 1.30 (55～60 ℃); Add 50% alcohol reflux 1.5 hours the 2nd time, filter.Add water for the 3rd time and refluxed 2 hours, filter, merge filtrate the 2nd time, the 3rd time, reclaim ethanol, being concentrated into relative density is 1.40 (55～60 ℃), and with the 1st time concentrated solution merging, mixing, making relative density is the extractum of 1.35～1.39 (55 ℃).Radix Notoginseng powder is broken into fine powder, mixes all with Radix Salviae Miltiorrhizae extractum, drying is made granule.With the Borneolum Syntheticum porphyrize, be mixed with above-mentioned granule, be pressed into 1000, or sugar coating, promptly.
Though above-mentioned technology can make most effective ingredient be kept, also can remove the impurity of a great deal of, this technology is adopted in discovering in recent years, makes much relevant with immunity polysaccharose substance and many trace element that very big loss be arranged; And the production cycle of this production technology is long, complex process, and the production cost height, finished product stability is poor, easily produces environmental pollution.
Membrane separation technique (Membrane Separation Technique) is an emerging high efficient separation technology, by internationally recognized be a most rising great high production tech of mid-term 20 end of the centurys to 21 century.Ultrafiltration (Ultrafiltration, UF) technology is a kind of membrane separation technique, its ultimate principle is to utilize fenestra selectivity sieve performance, with separation, purification and condensed matter.Hyperfiltration process is that the anisotropic membrane (being asymmetric membrane) that utilizes macromolecular material to make is a filter medium, under normal temperature condition, relies on certain pressure and flow velocity, makes flow of solution through face, forces low molecular weight substance to see through film, and polymer substance is trapped.
Because hyperfiltration process is a physical method, do not have and must heat repeatedly, there be not " phase " to change, the probability of destroying effective ingredient is few than other universal method, characteristics such as technological process is short, thereby its be applied to extract in the research of pharmaceutically active ingredient become increasingly active, portioned product moves towards commercial production from laboratory research.Human ultrafiltrations such as 304 Wang Shiling of hospital of PLA are extracted effective ingredient baicalin in the Radix Scutellariae, the result shows that ultrafiltration is excellent than well-established law all aspect productive rate, purity, and a ultrafiltration can reach the injection requirement, do not need again row refining, technology is simple, and the production cycle can shorten 1～2 times of (Wang Shiling, Zheng Dianbao " ultrafiltration is extracted the preliminary investigation of baicalin ", Chinese patent medicine research, 1988 (3): 5).Wang Shiling etc. have also further studied the optimum process condition of ultrafiltration extraction baicalin, it is the key that improves baicalin yield and quality that the experimental result proof is selected the ultrafilter membrane in suitable aperture (molecular cut off is 6000～10000) for use, the fluid temperature that raises simultaneously or reduction concentration, strict control pH value (pH=1.5 during acidify, pH=7.0 when alkali is molten), can significantly improve ultrasiltrated rate, obtain best output effect (Wang Shiling, " ultrafiltration is once extracted the technical study of baicalin ", Chinese patent medicine, 1994,16 (3): 2).Xu Jinlin etc. are with ultrafiltration (polysulfone membrane, molecular cut off 6000) is used for the preparation of phytic acid, the phytic acid yield is 86.4%, and than the phytate method raising 12.6% of routine, and ultrafiltration gained phytic acid contains Phos hardly, appearance transparent is close to colourless (Xu Jinlin, Xu Jie, Wang Yuanjin " membrane separation technique prepares the research of phytic acid ", Chinese Journal of Pharmaceuticals, 1994,25 (4): 150).He Changsheng etc. use hyperfiltration technique separation and purification steviol glycosides, and adopting ultrathin plate-type hyperfiltration device and molecular cut off is that 10000 cellulose acetate membrane (CA film) purifies field experimentation to steviol glycosides, and its technological process is rationally feasible.The ultrafilter stable performance, the decoloration performance and the removal of impurity of film are respond well, bubble problem (He Changsheng in the time of can solving precipitation that steviol glycosides usually occurs in producing and embedding preferably, WangBing Nan, Zhu Shanshan " applied research of steviol glycosides ultrafiltration ", water technology, 1994,20 (2): 89).Huang is improved oneself and is adopted the refining sasanguasaponin of ultrafilter membrane (molecular cut off is 4000 and 10000 polysulfone membrane), compare with the domestic bleaching that mostly adopts, recrystallize method, the alcohol ether sedimentation method and the basic salt sedimentation method, the ultrafiltration flow process is simple, the efficient height, expense is low, to removing oils and fats, pigment, saccharide and the strong impurity of other hydrophilic in the thick sasanguasaponin, can both producing a desired effect, (Huang is improved oneself, " ultrafiltrationmembrane process is made with extra care the sasanguasaponin pre-test " water technology, 1995,21 (2): 99).Guo Li Wei of Nanjing University of Traditional Chinese Medicine etc. has relatively studied water alcohol method and ultrafiltration is clarified the influence of Fructus Corni preparation to its preparation ingredient, the result confirms that ultrafiltration is more effective to saccharide impurity in the removal medicinal liquid, molecular cut off is that 10000 ultrafilter membrane does not have obviously influence to meliatin (molecular weight is 384), but being 1000 film, molecular cut off makes meliatin loss about 50% (Guo Liwei, Peng Guoping, Pan Yang etc. " the refining comparative study that contains the Fructus Corni Chinese medicine preparation of water alcohol method and membrane separation process ", Chinese patent medicine, 1999,21 (2): 59).Wang Chengzhang etc. adopt ultrafiltration (polysulfone membrane; molecular cut off 30000) separates with the ethanol extract of polyamide absorb-elute method Folium Ginkgo; purification; detect through high performance liquid chromatography (HPLC); the ginkgetin salidroside content is about 45%; yield is 0.5%～0.7%; more conventional steam distillation; the organic solvent extraction method is excellent; and in ultrafiltration technology, can reduce discharge of wastewater, the protection environment reduces production costs; (Wang Chengzhang increases economic efficiency; Yu Qing, Tan Weihong etc. " application of ultrafiltration in purification Folium Ginkgo flavone glycoside ", forestry science and technology communication; 1997, (2): 21).
Though hyperfiltration technique is applied to the production of Chinese medicine preparation its unique advantage is arranged, its degree of applying is still very limited, traces it to its cause, and remains in following problem:
(1) medicinal herb components complexity, particularly many compound preparations, effective ingredient are also unclear fully, therefore need to carry out very deep research before hyperfiltration technique is applied to Chinese herbal and crude drugs preparations.For example because the complexity of composition, do not carry out a large amount of pharmacology and clinical research test fully estimate ultrafiltration to Chinese medicine preparation in before the drug effect influence degree of each composition, ultrafiltration can not be applied to the production of most of Chinese medicine preparation.
(2) kind of membrane material is few, and membrane aperture distributes wide, and performance is understable.Used ultrafilter membrane material has cellulose acetate, polyacrylonitrile, polysulfones, SPSF, polysulfonamides etc. in Chinese medicine preparation production.By its affinity classification, be broadly divided into two classes: hydrophobic film material and hydrophilic film material to water.Hydrophilic film such as cellulose acetate, SPSF material is few to solute absorption, and molecular cut off is less, but poor heat stability, mechanical strength, chemical proof, antibacterium erosiveness are not high usually; Hydrophobic film materials such as polysulfones, the mechanical strength height, high temperature resistant, anti-solvent, anti-biodegradation, but because of containing a large amount of hydrophobicity genes or chain link in the strand, and have more electrostatic charge, thereby the permeable speed of film is low, contamination resistance is lower.
(3) pollution problem of film is to hinder hyperfiltration technique is moved towards the commercial Application stage by laboratory research biggest obstacle.In the ultra-filtration process of Chinese medicine preparation, when not good as if the medicinal liquid pretreating effect, face easily pollutes, and fenestra stops up, and making permeation flux is that productivity ratio descends, even cisco unity malfunction, and production efficiency reduces, and cost rises, and causes the shortening in service life of film.
(4) system of selection of membrane module is not set up as yet, the optimization of still needing of ultrafiltration parameter.The factor that influences the ultrafiltration effect is a lot, comprises the selection of membrane module, the cleaning method after the definite and ultrafilter of technological parameter uses etc.Therefore be applicable to ultrafiltration apparatus and the operating procedure that the ultrafiltration of Chinese medicine system is used, remain further to be studied.
The relevant practical application that utilizes ultrafiltration to prepare FUFANG DANSHEN PIAN, present document does not have any report as yet.Particularly, utilize ultrafiltration to carry out suitability for industrialized production is a technical barrier in this area always.
The inventor is through the effort of long-term and unremitting ground, by a large amount of experimental datas are analyzed, verified that ultrafiltration prepares the feasibility of medicine of the present invention, and determined suitable process condition, for the suitability for industrialized production of utilizing ultrafiltration to carry out medicine of the present invention provides concrete solution.
Summary of the invention
The Chinese medicine composition that the purpose of this invention is to provide the treatment angina pectoris that a kind of impurity is few, loss of effective components is little, it has overcome the deficiencies in the prior art, solve the difficult problem of suitability for industrialized production ultrafiltration technology condition operability, and on prescription, increased the cardiac stimulant effect of QI invigorating.
The present invention realizes by following technical step: with Radix Salviae Miltiorrhizae, Radix Notoginseng, Borneolum Syntheticum and the Radix Astragali is crude drug, is prepared according to following steps:
(1) Radix Salviae Miltiorrhizae, Radix Notoginseng, the Radix Astragali are mixed or make water extract or alcohol extract separately;
(2) described extracting solution being carried out predefecation handles;
(3) further described extracting solution is carried out hyperfiltration treatment;
(4) ultrafiltrate is concentrated, add Borneolum Syntheticum, make preparation according to a conventional method.
The proportioning of above-mentioned raw materials medicine is counted by weight: Radix Salviae Miltiorrhizae 20～97, Radix Notoginseng 2～79, Borneolum Syntheticum 0.2～3, the Radix Astragali 10～40; Be preferably: Radix Salviae Miltiorrhizae 63.0～94.0, Radix Notoginseng 4.0～35.0, Borneolum Syntheticum 0.5～2.0, the Radix Astragali 15～30; More preferably: Radix Salviae Miltiorrhizae 75.2～90, Radix Notoginseng 9～23.5, Borneolum Syntheticum 0.5～1.3, the Radix Astragali 20～25.
In the technology of the present invention step (1), alcohol extract can be the extracting solution of the lower alcohol of variable concentrations such as methanol, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutanol etc. or the extracting solution of its mixture.Carrying out next step predefecation after alcohol extract can not concentrate or suitably concentrate handles.
In the technology of the present invention step (2), preliminary clarifying treatment can be carried out coarse filtration with general material such as gauze, tiffany etc., the also available material such as the ceramic membrane of specialty carry out microfiltration, also can behind high speed centrifugation, divide and get supernatant, adsorption clarifications such as also available flocculating agent such as flocculate with chitosan clarifier, 101 fruit juice clarifiers, ZTC1+1 natural clarifying agent, Ovum Gallus domesticus album flocculating agent and remove particle bigger in the medicinal liquid, also available alcohol deposition method is removed most impurity.Both can singly use above-mentioned defecation method, but also use in conjunction, coarse filtration-adsorption clarification for example, adsorption clarification-high speed centrifugation, coarse filtration-microfiltration, coarse filtration-precipitate with ethanol etc.After can not concentrating or suitably concentrate, the solution that predefecation is handled carries out next step ultrafiltration; Preferably do not concentrate the ultrafiltration of promptly carrying out next step.
In the technology of the present invention step (3), the used ultrafilter membrane of ultrafiltration can be cellulose diacetate film (CA), three cellulose acetate membrane (CTA), cyanoethyl cellulose film (CN-CA), polysulfone membrane (PS), sulfonated polysulfone membrane (SPS), poly (ether sulfone) film (PES), sulfonated polyether sulfone film (SPES), polysulfonamides film (PSA), phenolphthalein side group polyarylsulfone (PAS) film (PDS), polyvinylidene fluoride film (PVDF), polyacrylonitrile film (PAN), polyimide film (N), cellulose membrane, methyl methacrylate-acrylonitrile copolymer film (MMA-AN), polyacrylonitrile/cellulose diacetate (PAN/CA) blend film, the dynamically ultrafilter membrane that forms, and the Modified Membrane of above-mentioned film.Be preferably cellulose diacetate film (CA), three cellulose acetate membrane (CTA), polysulfone membrane (PS), sulfonated polysulfone membrane (SPS), poly (ether sulfone) film (PES), sulfonated polyether sulfone film (SPES), polysulfonamides film (PSA), polyvinylidene fluoride film (PVDF), polyacrylonitrile film (PAN).
The molecular cut off of above-mentioned ultrafilter membrane is generally 6000～80000, is preferably 10000～70000, and the best is 20000～50000.
Ultrafiltration both can be adopted cross flow filter, also can adopt dead-end filtration, but preferred cross flow filter.
The operating condition of ultrafiltration technology is as follows:
(1) the inlet pressure of ultrafiltration is 0.1～0.5MPa, is preferably 0.1～0.35Mpa, and the best is 0.25～0.35Mpa; The liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.5～0.25kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1～0.2Mpa.
(2) the feed liquid flow velocity is 1.0～4.0m/s, is preferably 2.0～3.0m/s.In the ultra-filtration process, adopt the fluctuation of periodicity flow so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0～2.0m/s.
(3) feed high-pressure inert gas such as nitrogen in the ultrafiltration system discontinuous, form the gas-liquid stream of pulses, the cycle is that 0.5h～2h ventilates once, each 1 minute.
(3) feed temperature is 15～50 ℃, is preferably 20～40 ℃.
(4) when feed liquid stock solution is concentrated 1/15～1/5, add water or dilute alcohol solution ultrafiltration 1～2 time again; Be preferably when feed liquid stock solution is concentrated 1/12～1/8, add water or dilute alcohol solution ultrafiltration 1～2 time again.
(5) pH value of feed liquid is controlled at 5～9, is preferably 6.0～7.5;
(6) backwash condition: backwashing pressure is 0.15～2.5MPa, and backwashing period is that 0.5～1.5h, backwashing time are 1min～10min.When ultrafiltration module use in parallel is replaced the method for recoil, wherein a cover or a few cover carry out normal ultrafiltration and distribute the recoil ultrafilter membrane of another set of or several grip assemblies of a part of filtrate, exchange is carried out behind the certain interval of time, generally is work 10～20min, recoil 30sec～3min.
(7) the Chemical cleaning cycle is 0.5 month～February, the Chemical cleaning medicament is generally diluted acid, diluted alkaline, surfactant, be preferably diluted alkaline, 0.5%～4.0% sodium hydroxide for example, the mixed solution of 1.5% sodium hydroxide and 2% sodium hypochlorite etc., pH value is 10～12, and cleaning pressure is 0.05～1.0MPa.After cleaning with chemical, the flushing of reuse water is near neutral.
In ultra-filtration process, both periodic pressure oscillation or the fluctuation of periodicity flow or periodicity fed noble gas separately, also can unite use, be periodic pressure fluctuation and periodically flow fluctuation associating use, perhaps the periodic pressure fluctuation is with periodically feeding noble gas unites use, perhaps periodically the flow fluctuation is with periodically feeding noble gas unites use, and perhaps the three unites use together.
In the technology of the present invention step (4), ultrafiltrate is condensed into extractum after, make preparation more according to a conventional method.For example, can be mixed and made into tablet, capsule, granule, oral liquid, slow releasing preparation, controlled release preparation, gel, ointment, ointment, cream, suppository, injection, injectable powder, patch, drop pill, suspensoid or the like with adjuvant on any or more than one pharmaceuticss such as starch, dextrin, lactose, microcrystalline Cellulose, hydroxypropyl methylcellulose, Polyethylene Glycol, magnesium stearate, micropowder silica gel, xylitol, lactose, glucose, glycine, mannitol, glycine etc.
The clinical observation of experimental example Drug therapy angina pectoris of the present invention
1 clinical data
1.1 out-patient's 96 examples of physical data angina pectoris are divided into 64 routine treatment groups and 32 routine matched groups at random.Diagnostic criteria for coronary heart disease is with reference to international heart association and WHO diagnostic criteria for coronary heart disease.All under resting state, obvious ischemia performance is all arranged before the case treatment through the electrocardiogram inspection.64 examples are organized in treatment, male's 48 examples wherein, women's 16 examples, 48～76 years old age, average 61 years old, stable angina pectoris 52 examples wherein, unstable angina pectoris 9 examples, old myocardial infarction 3 examples.Matched group 32 examples, male's 23 examples wherein, women's 9 examples, 46～76 years old age, average 62 years old, stable angina pectoris 22 examples wherein, unstable angina pectoris 7 examples, old myocardial infarction 3 examples.Learn by statistics and handle, two groups of clinical datas have comparability (P＞0.05).
1.2 oral medicine of the present invention, 3 slices/time, 3 times/day are organized in the Therapeutic Method treatment.The oral sorbitrate of matched group, 10mg/ time, 3 times/day.Took medicine continuously 30 days is a course of treatment.Observe patient's angina pectoris attacks number of times, degree before and after the treatment, and make electrocardiogram, blood fat, hemorheology, blood, routine urinalysis and liver, kidney function test.
1.3 efficacy assessment standardization is by national criterion of therapeutical effect evaluation curative effect to treat angina pectoris and ECG curative effect.Curative effect to treat angina pectoris, produce effects: equal labor intensity does not cause that angina pectoris or angina pectoris attacks number of times, degree and persistent period reduce greater than 80%; Effectively: angina pectoris attacks number of times, degree and persistent period reduce less than 50%～80%; Invalid: angina pectoris attacks number of times, degree and persistent period reduce less than 50%; Increase the weight of: angina pectoris attacks number of times, degree and persistent period increase.ECG curative effect, produce effects: tranquillization ECG recovers normal, or (with) submaximal exercise test transfers feminine gender to by the positive or exercise tolerance test ECG is descended more than the treatment back rise 0.5mm by ischemic ST, but do not reach normal level, or the negative T wave that mainly leads shoals and reaches more than 50% or the T ripple transfers to uprightly by smooth, and exercise tolerance rises more than 1 grade: invalid: relevant various ECG are preceding basic identical with treatment; Increase the weight of: tranquillization ECG, the ST section before the treatment more than the decline 0.5mm, be inverted by the T ripple that mainly leads, or (with) submaximal exercise test before the treatment exercise tolerance descend more than 1 grade.
2 results
2.1 two groups of curative effect to treat angina pectoris relatively, sees Table 1.
Table 1 liang group curative effect to treat angina pectoris relatively
2.2 two groups of ECG curative effect relatively, sees Table 2.
Table 2 liang group ECG curative effect relatively
2.3 relatively, see Table 3 before and after two groups of lipid therapies
Compare before and after the table 3 liang group lipid therapy (x ± s)
Annotate: * group internal therapy front and back are than P＜0.01
2.4 relatively, see Table 4 before and after two groups of hemorheology treatments.
Table 4 liang group hemorheology comparison (x ± s)
Annotate: compare * P＜0.05, * P＜0.01 before and after the group internal therapy
The specific embodiment
The invention will be further elaborated below in conjunction with embodiment.These embodiment only are used to the purpose that exemplifies, rather than limit the present invention by any way.
Embodiment one
Crude drug adopts Radix Salviae Miltiorrhizae 375g, Radix Notoginseng 118g, Borneolum Syntheticum 8g, Radix Astragali 100g.
Obtain the ethanol extract of the Radix Salviae Miltiorrhizae and the Radix Astragali with the ethanol extraction Radix Salviae Miltiorrhizae and the Radix Astragali, with this extracting liquid filtering, collect filtrate with gauze.Filtrate is that 6000 cellulose diacetate film carries out ultrafiltration with molecular cut off, and filter type adopts cross flow filter.The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.1Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.5kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1Mpa.The feed liquid flow velocity is 1.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 0.5h ventilates once each 1 minute.Feed temperature is 15 ℃, when feed liquid stock solution is concentrated 1/15, adds water or dilute alcohol solution ultrafiltration 1 time again, and the pH value of feed liquid is controlled at 5.Backwashing pressure is 0.15MPa, and backwashing period is that 0.5h, backwashing time are 1min.When with the in parallel method of using alternately recoil of ultrafiltration module, wherein a cover or a few cover carry out normal ultrafiltration and distribute the recoil ultrafilter membrane of another set of or several grip assemblies of a part of filtrate, and exchange is carried out behind the certain interval of time, work 10min, recoil 30sec.The Chemical cleaning cycle is 0.5 month, and the Chemical cleaning medicament is the mixed solution of 0.5%～4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, and pH value is 10～12, and cleaning pressure is 0.05MPa.After cleaning with chemical, the flushing of reuse water is near neutral.
Described ultrafiltrate concentrated obtain the extractum that relative density is 1.35～1.39 (55 ℃).Radix Notoginseng powder is broken into fine powder, mixes all with above-mentioned extractum, drying is made granule.With the Borneolum Syntheticum porphyrize, be mixed with above-mentioned granule, be pressed into 1000, or sugar coating, promptly.
Embodiment two
Crude drug adopts Radix Salviae Miltiorrhizae 465g, Radix Notoginseng 30g, Borneolum Syntheticum 8g, Radix Astragali 85g.
Obtain the ethanol extract of the Radix Salviae Miltiorrhizae and the Radix Astragali with the ethanol extraction Radix Salviae Miltiorrhizae and the Radix Astragali, carry out microfiltration, collect filtrate with ceramic membrane.Filtrate is that 80000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and filter type adopts dead-end filtration.The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.5Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.25kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 4.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 50 ℃, when feed liquid stock solution is concentrated 1/5, adds water or dilute alcohol solution ultrafiltration 2 times again, and the pH value of feed liquid is controlled at 9.Backwashing pressure is 2.5MPa, and backwashing period is that 1.5h, backwashing time are 10min.When with the in parallel method of using alternately recoil of ultrafiltration module, wherein a cover or a few cover carry out normal ultrafiltration and distribute the recoil ultrafilter membrane of another set of or several grip assemblies of a part of filtrate, and exchange is carried out behind the certain interval of time, work 20min, recoil 3min.The Chemical cleaning cycle is 2 months, and the Chemical cleaning medicament is the mixed solution of 0.5%～4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, and pH value is 10～12, and cleaning pressure is 1.0MPa.After cleaning with chemical, the flushing of reuse water is near neutral.
Described ultrafiltrate concentrated obtain the Radix Salviae Miltiorrhizae extractum that relative density is 1.35～1.39 (55 ℃).Radix Notoginseng powder is broken into fine powder, mixes all,, be mixed, add 3% polyvidone alcoholic solution system soft material, cross 18 mesh sieve system granules with above-mentioned granule with the Borneolum Syntheticum porphyrize with above-mentioned extractum, 60 ℃ of dryings 30～45 minutes, granulate, the adding Pulvis Talci, mixing fills in capsule, promptly.
Embodiment three
Crude drug adopts Radix Salviae Miltiorrhizae 260g, Radix Notoginseng 165g, Borneolum Syntheticum 7g, Radix Astragali 170g.
Obtain blended ethanol extract with ethanol extraction Radix Salviae Miltiorrhizae, Radix Notoginseng and the Radix Astragali, get supernatant dividing behind this extracting solution high speed centrifugation.With this liquid molecular cut off is that 50000 polysulfone membrane is carried out ultrafiltration, and filter type adopts cross flow filter.The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds water or dilute alcohol solution ultrafiltration 2 times again, and the pH value of feed liquid is controlled at 7.5.Backwashing pressure is 2.5MPa, and backwashing period is that 1.5h, backwashing time are 10min.When with the in parallel method of using alternately recoil of ultrafiltration module, wherein a cover or a few cover carry out normal ultrafiltration and distribute the recoil ultrafilter membrane of another set of or several grip assemblies of a part of filtrate, and exchange is carried out behind the certain interval of time, work 20min, recoil 3min.The Chemical cleaning cycle is 2 months, and the Chemical cleaning medicament is the mixed solution of 0.5%～4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, and pH value is 10～12, and cleaning pressure is 1.0MPa.After cleaning with chemical, the flushing of reuse water is near neutral.
Described ultrafiltrate concentrated obtain the extractum that relative density is 1.35～1.39 (55 ℃).Drying is made granule.With the Borneolum Syntheticum porphyrize, be mixed with above-mentioned granule, add an amount of magnesium stearate mix homogeneously, be pressed into 1000, or sugar coating, promptly.
Embodiment four
Crude drug adopts Radix Salviae Miltiorrhizae 490 grams, Radix Notoginseng 84 grams, Borneolum Syntheticum 6 grams, Radix Astragali 60g.
Radix Salviae Miltiorrhizae, Radix Notoginseng and the Milkvetch Root of coarse pulverization are added in the extraction pot, add 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out the second time and extracts, and adds 4 times of water gagings, fries in shallow oil 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate is that 6000 cellulose diacetate film carries out ultrafiltration with molecular cut off, and filter type adopts cross flow filter.The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.1Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.5kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.1Mpa.The feed liquid flow velocity is 1.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 1.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 0.5h ventilates once each 1 minute.Feed temperature is 15 ℃, when feed liquid stock solution is concentrated 1/15, adds water or dilute alcohol solution ultrafiltration 1 time again, and the pH value of feed liquid is controlled at 5.Backwashing pressure is 0.15MPa, and backwashing period is that 0.5h, backwashing time are 1min.When with the in parallel method of using alternately recoil of ultrafiltration module, wherein a cover or a few cover carry out normal ultrafiltration and distribute the recoil ultrafilter membrane of another set of or several grip assemblies of a part of filtrate, and exchange is carried out behind the certain interval of time, work 10min, recoil 30sec.The Chemical cleaning cycle is 0.5 month, and the Chemical cleaning medicament is the mixed solution of 0.5%～4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, and pH value is 10～12, and cleaning pressure is 0.05MPa.After cleaning with chemical, the flushing of reuse water is near neutral.
Described ultrafiltrate concentrated obtain the extractum that relative density is 1.32～1.40 (55 ℃), add Borneolum Syntheticum, mix homogeneously, with the lactose fluidisation, drying is made granule, promptly in the batch (-type) fluid bed.
Embodiment five
Crude drug adopts Radix Salviae Miltiorrhizae 242 grams, Radix Notoginseng 255 grams, Borneolum Syntheticum 4 grams, Radix Astragali 100g.
Radix Salviae Miltiorrhizae, Radix Notoginseng and the Milkvetch Root of coarse pulverization are added in the extraction pot, add 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out the second time and extracts, and adds 4 times of water gagings, fries in shallow oil 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate is that 80000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and filter type adopts dead-end filtration.The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.5Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.25kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 4.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 50 ℃, when feed liquid stock solution is concentrated 1/5, adds water or dilute alcohol solution ultrafiltration 2 times again, and the pH value of feed liquid is controlled at 9.Backwashing pressure is 2.5MPa, and backwashing period is that 1.5h, backwashing time are 10min.When with the in parallel method of using alternately recoil of ultrafiltration module, wherein a cover or a few cover carry out normal ultrafiltration and distribute the recoil ultrafilter membrane of another set of or several grip assemblies of a part of filtrate, and exchange is carried out behind the certain interval of time, work 20min, recoil 3min.The Chemical cleaning cycle is 2 months, and the Chemical cleaning medicament is the mixed solution of 0.5%～4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, and pH value is 10～12, and cleaning pressure is 1.0MPa.After cleaning with chemical, the flushing of reuse water is near neutral.
Described ultrafiltrate concentrated obtain the extractum that relative density is 1.32～1.40 (55 ℃), add Borneolum Syntheticum, again with mannitol 30g, calcium disodium edetate 5g, distilled water 5ml, behind the said components mixing, lyophilization, packing, promptly.
Embodiment six
Crude drug adopts Radix Salviae Miltiorrhizae 162 grams, Radix Notoginseng 295 grams, Borneolum Syntheticum 4 grams, Radix Astragali 138g.
Radix Salviae Miltiorrhizae, Radix Notoginseng and the Milkvetch Root of coarse pulverization are added in the extraction pot, add 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out the second time and extracts, and adds 4 times of water gagings, fries in shallow oil 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate is that 50000 polysulfone membrane is carried out ultrafiltration with molecular cut off, and filter type adopts cross flow filter.The operating condition of ultrafiltration technology is: the inlet pressure of ultrafiltration is 0.35Mpa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.20kPa.The ultrafiltration initial stage is adopted lower pressure, slowly boosts then; In ultra-filtration process, adopt the periodic pressure fluctuation, the pressure wave moment is 0.2Mpa.The feed liquid flow velocity is 3.0m/s, in the ultra-filtration process, adopts periodically flow fluctuation so that produce pulsating flow or non-stationary flow in membrane channels, the flow speed wave moment is 2.0m/s, feeds nitrogen in the ultrafiltration system discontinuous, forms the gas-liquid stream of pulses, cycle is that 2h ventilates once each 1 minute.Feed temperature is 40 ℃, when feed liquid stock solution is concentrated 1/8, adds water or dilute alcohol solution ultrafiltration 2 times again, and the pH value of feed liquid is controlled at 7.5.Backwashing pressure is 2.5MPa, and backwashing period is that 1.5h, backwashing time are 10min.When with the in parallel method of using alternately recoil of ultrafiltration module, wherein a cover or a few cover carry out normal ultrafiltration and distribute the recoil ultrafilter membrane of another set of or several grip assemblies of a part of filtrate, and exchange is carried out behind the certain interval of time, work 20min, recoil 3min.The Chemical cleaning cycle is 2 months, and the Chemical cleaning medicament is the mixed solution of 0.5%～4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, and pH value is 10～12, and cleaning pressure is 1.0MPa.After cleaning with chemical, the flushing of reuse water is near neutral.
Described ultrafiltrate concentrated obtain the extractum that relative density is 1.32～1.40 (55 ℃),, be pressed into tablet this extractum and Borneolum Syntheticum and an amount of magnesium stearate mix homogeneously.
Claims (12)
1. a Chinese medicine composition for the treatment of angina pectoris is characterized in that, it is by Radix Salviae Miltiorrhizae 20～97, Radix Notoginseng 2～79, and Borneolum Syntheticum 0.2～3, the Radix Astragali 10～40 raw materials in weight portion are prepared from by the following method:
(a) Radix Salviae Miltiorrhizae, Radix Notoginseng, the Radix Astragali are mixed or make water extract or alcohol extract separately;
(b) described extracting solution being carried out predefecation handles;
(c) further described extracting solution is carried out hyperfiltration treatment;
(d) ultrafiltrate is concentrated, add Borneolum Syntheticum, make preparation according to a conventional method; The operating procedure condition of described hyperfiltration treatment is as follows:
The inlet pressure of ultrafiltration is 0.1～0.5MPa, and the liquid outlet pressure ratio inlet pressure of ultrafiltration hangs down 0.25～0.5kPa; Feed temperature is 15～50 ℃; The pH value of feed liquid is controlled at 5～9; When feed liquid stock solution is concentrated 1/15～1/5, add water or dilute alcohol solution ultrafiltration 1～2 time again.
2. Chinese medicine composition as claimed in claim 1 is characterized in that, the weight portion proportioning of described raw material is:
Radix Salviae Miltiorrhizae 63.0～94.0,
Radix Notoginseng 4.0～35.0,
Borneolum Syntheticum 0.5～2.0,
The Radix Astragali 15～30.
3. Chinese medicine composition as claimed in claim 2 is characterized in that, the weight portion proportioning of described raw material is:
Radix Salviae Miltiorrhizae 75.2～90,
Radix Notoginseng 9～23.5,
Borneolum Syntheticum 0.5～1.3,
The Radix Astragali 20～25.
4. Chinese medicine composition as claimed in claim 1 is characterized in that, described alcohol extract is to be selected from the following lower alcohol or the extracting solution of its mixture: methanol, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutanol.
5. Chinese medicine composition as claimed in claim 1 is characterized in that, described alcohol extract is an ethanol extract.
6. Chinese medicine composition as claimed in claim 1 is characterized in that, what described step (a) obtained is the ethanol extract of Radix Salviae Miltiorrhizae, Radix Notoginseng and the Radix Astragali.
7. Chinese medicine composition as claimed in claim 1 is characterized in that, what described step (a) obtained is the aqueous extract that Radix Salviae Miltiorrhizae, Radix Notoginseng and the Radix Astragali are mixed and made into.
8. Chinese medicine composition as claimed in claim 1 is characterized in that described predefecation is treated to coarse filtration-adsorption clarification, adsorption clarification-high speed centrifugation, coarse filtration-microfiltration or coarse filtration-precipitate with ethanol.
9. Chinese medicine composition as claimed in claim 1, it is characterized in that, the used ultrafilter membrane of described hyperfiltration treatment is selected from: cellulose diacetate film, three cellulose acetate membrane, cyanoethyl cellulose film, polysulfone membrane, sulfonated polysulfone membrane, poly (ether sulfone) film, sulfonated polyether sulfone film, polysulfonamides film, phenolphthalein side group polyarylsulfone (PAS) film, polyvinylidene fluoride film, polyacrylonitrile film, polyimide film, cellulose membrane, methyl methacrylate-acrylonitrile copolymer film, polyacrylonitrile/cellulose diacetate blend film, the dynamically ultrafilter membrane that forms, and the Modified Membrane of above-mentioned film; The molecular cut off of its ultrafilter membrane is 6000～80000.
10. Chinese medicine composition as claimed in claim 9, it is characterized in that, described ultrafilter membrane is selected from: cellulose diacetate film, three cellulose acetate membrane, polysulfone membrane, sulfonated polysulfone membrane, poly (ether sulfone) film, sulfonated polyether sulfone film, polysulfonamides film, polyvinylidene fluoride film, polyacrylonitrile film; The molecular cut off of its ultrafilter membrane is 10000～70000.
11. Chinese medicine composition as claimed in claim 1 is characterized in that, in the process of described ultrafiltration separately or unite the following method that adopts: periodic pressure fluctuation, periodically flow fluctuation, feed noble gas off and on; Wherein the pressure wave moment of periodic pressure fluctuation is 0.1～0.2Mpa, and periodically the flow speed wave moment of flow fluctuation is 1.0～2.0 meter per seconds, feeds noble gas off and on and be ventilation in 0.5 hour～2 hours once, each 1 minute.
12. Chinese medicine composition as claimed in claim 1, it is characterized in that described preparation contains any or more than one are selected from following pharmaceutics adjuvant: starch, dextrin, lactose, microcrystalline Cellulose, hydroxypropyl methylcellulose, Polyethylene Glycol, magnesium stearate, micropowder silica gel, xylitol, lactose, glucose, glycine, mannitol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410072945 CN1778340B (en) | 2004-11-26 | 2004-11-26 | Chinese medicine composition for treating coronary heart disease and angina cordis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410072945 CN1778340B (en) | 2004-11-26 | 2004-11-26 | Chinese medicine composition for treating coronary heart disease and angina cordis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1778340A CN1778340A (en) | 2006-05-31 |
| CN1778340B true CN1778340B (en) | 2010-11-10 |
Family
ID=36768877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410072945 Active CN1778340B (en) | 2004-11-26 | 2004-11-26 | Chinese medicine composition for treating coronary heart disease and angina cordis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1778340B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085018B (en) * | 2006-06-08 | 2012-01-04 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root, notoginseng, radix astragali and borneol or storax and its preparation |
| CN101084992B (en) * | 2006-06-08 | 2012-03-07 | 天津天士力制药股份有限公司 | Medicinal composition containing safflower and ginseng, preparation method and preparation |
| CN101084994B (en) * | 2006-06-08 | 2012-02-22 | 天津天士力制药股份有限公司 | Medicinal composition containing red sage root and ginseng, preparation method and preparation |
| CN101085007B (en) * | 2006-06-08 | 2011-10-05 | 天津天士力制药股份有限公司 | Composition containing erigeron breviscapus for treating cardiovascular diseases and its preparation |
| CN101084993B (en) * | 2006-06-08 | 2012-03-07 | 天津天士力制药股份有限公司 | Medicinal composition containing dalbergia and storax, preparation method and preparation |
| CN109954102A (en) * | 2017-12-25 | 2019-07-02 | 张聚兵 | A kind of Chinese medicine preparation compound Danshen Root is scattered |
| CN115154500A (en) * | 2022-05-09 | 2022-10-11 | 云南赛森生物科技有限公司 | Traditional Chinese medicine composition capable of improving blood flow and resisting anoxia and preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1375316A (en) * | 2002-02-07 | 2002-10-23 | 天津天士力制药股份有限公司 | Chinese medicine prepn. for treating coronary heart disease and angina pactoris and its prepn. process |
-
2004
- 2004-11-26 CN CN 200410072945 patent/CN1778340B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1375316A (en) * | 2002-02-07 | 2002-10-23 | 天津天士力制药股份有限公司 | Chinese medicine prepn. for treating coronary heart disease and angina pactoris and its prepn. process |
Non-Patent Citations (10)
| Title |
|---|
| 刘洪谦，屈凌波，贾金付.生脉饮口服液超滤技术研究.中草药27 4.1996,27(4),209-211. |
| 刘洪谦,屈凌波,贾金付.生脉饮口服液超滤技术研究.中草药27 4.1996,27(4),209-211. * |
| 国家药典委员会.中华人民共和国药典 2000版.化学工业出版社,2000,519. |
| 国家药典委员会.中华人民共和国药典 2000版.化学工业出版社,2000,519. * |
| 李淑莉，刘振丽，宋志前.超滤法在中药制剂纯化工艺中的应用研究进展.中药材26 12.2003,26(12),898-902. |
| 李淑莉,刘振丽,宋志前.超滤法在中药制剂纯化工艺中的应用研究进展.中药材26 12.2003,26(12),898-902. * |
| 郝莉.超滤法制备丹参注射液的工艺改进.中草药27 8.1996,27(8),471. |
| 郝莉.超滤法制备丹参注射液的工艺改进.中草药27 8.1996,27(8),471. * |
| 黄伟文，梁云，邵霞.超滤法制备中药注射液的质量研究.水处理技术14 2.1988,14(2),87-91. |
| 黄伟文,梁云,邵霞.超滤法制备中药注射液的质量研究.水处理技术14 2.1988,14(2),87-91. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1778340A (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1778340B (en) | Chinese medicine composition for treating coronary heart disease and angina cordis | |
| CN1778335B (en) | Chinese medicine for treating coronary heart disease and angina cordis | |
| CN101085013B (en) | Traditional Chinese medicinal composition containing red sage root, safflower, radix astragali and dalbergia oil and its preparation | |
| CN1778333B (en) | Chinese medicine for treating coronary heart disease and angina cordis | |
| CN1778338B (en) | Chinese medicine composition for treating coronary heart disease and angina cordis | |
| CN1778337B (en) | Preparation of compound Danshen Root tablet | |
| CN1778342B (en) | Chinese medicine composition for treating coronary heart disease | |
| CN101085005B (en) | Traditional Chinese medicinal composition containing red sage root, ligusticum wallichii and dalbergia oil and its preparation | |
| CN1778343B (en) | Medicine dropping pill for treating coronary heart disease | |
| CN1778322B (en) | Chinese medicine for treating cardiovascular disease | |
| CN1778334B (en) | Chinese Medicine dropping pill for treating coronary heart disease and angina cordis | |
| CN1778352B (en) | Chinese medicine composition for treating cardiovascular disease | |
| CN1778344B (en) | Medicine for treating coronary heart disease | |
| CN1778345B (en) | Chinese medicine dropping pill for treating coronary heart disease | |
| CN1778353B (en) | Chinese medicine dropping ball for treating cardiovascular disease | |
| CN1778354B (en) | Chinese medicine dropping ball for coronary heart disease and angina cordis | |
| CN1778339B (en) | Medicine dropping pill for treating coronary heart disease and angina cordis | |
| CN1778346B (en) | Medicine for treating coronary heart disease | |
| CN101085056B (en) | Traditional Chinese medicinal composition containing red sage root, radix paeoniae rubrathe and dalbergia oil and its preparation | |
| CN1778326B (en) | Medicine for treating cardiovascular disease | |
| CN1778341B (en) | Medicine dropping pill for treating coronary heart disease and angina cordis | |
| CN101085015B (en) | Traditional Chinese medicinal composition containing red sage root, notoginseng, safflower and dalbergia oil and its preparation | |
| CN101088522B (en) | Chinese medicine composition containing red sage, notoginseng and musk or muskone and its prepn | |
| CN101084993B (en) | Medicinal composition containing dalbergia and storax, preparation method and preparation | |
| CN1778327B (en) | Medicine dropping pill for treating cardiovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |